24/7 Market News Snapshot 24 March, 2025 – Codexis, Inc. (NASDAQ:CDXS)

March 24, 2025

DENVER, Colo., 24 March, 2025 (247marketnews.com) – (NASDAQ:CDXS) are discussed in this article.
Codexis, Inc. is experiencing significant momentum in its market performance, with shares recently trading at $3.095 after opening at $2.64, reflecting an impressive increase of 21.37%. This surge follows a close of $2.55 in the previous session, signaling heightened investor confidence and market enthusiasm. With a trading volume of 1.07 million shares, interest in Codexis appears to be growing substantially, suggesting an optimistic outlook for the company as analysts await further developments.

In addition to its stock performance, Codexis has reached a pivotal milestone by securing its first revenue-generating contract for the production of small interfering RNA (siRNA) material at its ECO Synthesis™ Innovation Lab. This achievement highlights the effective transition of Codexis’s core ECO Synthesis™ enzymes from research phases to active development and scale-up, solidifying the company’s role in providing advanced enzymatic solutions for therapeutic manufacturing.

The ECO Synthesis™ platform represents Codexis’s commitment to fostering more efficient and sustainable manufacturing practices. The successful completion of the first generation of its core enzymes positions the company to meet burgeoning industrial capacity demands while maintaining stringent quality and performance standards.

Stephen Dilly, MBBS, PhD, Chairman and CEO of Codexis, expressed his enthusiasm for the contract, noting its significance in building on prior successes and emphasizing the company’s innovative research efforts. The upcoming presentations at scientific meetings will showcase the groundbreaking capabilities of the ECO Synthesis™ platform, which aims to surpass traditional chemical methods in key process parameters. As the RNA interference (RNAi) therapeutics market expands, Codexis is poised to leverage its innovative technologies to enhance pharmaceutical manufacturing efficiency, focusing on yield optimization, reduced energy consumption, and minimized waste.

Related news for (CDXS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.